Studied in trials
Studied regimens (not recommendations)
Studied in trials — not a recommended dose
- EASE-1: 10 mg SC twice weekly (once-weekly arm did not meet primary endpoint).
- Dosing self-administered via single-use autoinjector after training.
Dose evidence detail — Glepaglutide
Detailed dose evidence documented for Glepaglutide in its monograph — reference only, not dosing recommendations.
Reference only — not a dosing recommendation.
Not established
No approved labeled regimen
No established or recommended human dose.
- No established or recommended human dose.
Not established
What is not established
- Comparison to teduglutide (the only approved GLP-2 for SBS-IF in the US) or apraglutide
- Optimal duration of therapy
- Efficacy in SBS subtypes not represented in EASE-1
- Use in paediatric SBS
Glepaglutide — section dose et administration de la monographie